News Updates

More Articles Back to Article

Novartis to offload some assets from ophthalmology portfolio

Novartis is considering the sale of some ophthalmology assets to focus on other growth areas, according to unnamed sources familiar with the matter. Assets that may be put up for sale include Xiidra, or lifitegrast ophthalmic solution, and Beovu, or brolucizumab-dbll. BioSpace (San Francisco) (3/14)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!